Analyzing Medivir AB (publ) (OTCMKTS:MVRBF) and Applied Dna Sciences (NASDAQ:BNBX)

Applied Dna Sciences (NASDAQ:BNBX) and Medivir AB (publ) (OTCMKTS:MVRBF) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.

Valuation & Earnings

This table compares Applied Dna Sciences and Medivir AB (publ)”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Dna Sciences	$2.09 million	0.52	-$15.16 million	($36.76)	-0.00
Medivir AB (publ)	N/A	N/A	N/A	$32.14	0.03

Medivir AB (publ) has lower revenue, but higher earnings than Applied Dna Sciences. Applied Dna Sciences is trading at a lower price-to-earnings ratio than Medivir AB (publ), indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

22.2% of Applied Dna Sciences shares are owned by institutional investors. Comparatively, 23.2% of Medivir AB (publ) shares are owned by institutional investors. 6.1% of Applied Dna Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Applied Dna Sciences and Medivir AB (publ)’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Applied Dna Sciences	-1,647.25%	-349.95%	-283.96%
Medivir AB (publ)	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Applied Dna Sciences and Medivir AB (publ), as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Dna Sciences	1	0	0	0	1.00
Medivir AB (publ)	0	0	0	0	0.00

Summary

Medivir AB (publ) beats Applied Dna Sciences on 6 of the 9 factors compared between the two stocks.

About Applied Dna Sciences

Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company’s supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.

About Medivir AB (publ)

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.